Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ORGO 
Organogenesis Holdings Inc (ORGO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: ORGO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8
1 Year Target Price $8
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.6% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 536.61M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 4 | Beta 1.69 | 52 Weeks Range 2.61 - 6.71 | Updated Date 10/30/2025 |
52 Weeks Range 2.61 - 6.71 | Updated Date 10/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When - | Estimate 0.0629 | Actual - |
Profitability
Profit Margin -1.92% | Operating Margin (TTM) -10.72% |
Management Effectiveness
Return on Assets (TTM) -2.01% | Return on Equity (TTM) -2.63% |
Valuation
Trailing PE - | Forward PE 12.32 | Enterprise Value 632325109 | Price to Sales(TTM) 1.25 |
Enterprise Value 632325109 | Price to Sales(TTM) 1.25 | ||
Enterprise Value to Revenue 1.47 | Enterprise Value to EBITDA 198.16 | Shares Outstanding 126857709 | Shares Floating 55469802 |
Shares Outstanding 126857709 | Shares Floating 55469802 | ||
Percent Insiders 46.69 | Percent Institutions 56.7 |
Upturn AI SWOT
Organogenesis Holdings Inc
Company Overview
History and Background
Organogenesis Holdings Inc. was founded in 1985. It initially focused on bioengineered skin substitutes and has expanded into a broader portfolio of regenerative medicine products. The company went public via a SPAC merger in 2018.
Core Business Areas
- Advanced Wound Care: Focuses on products for chronic and acute wound healing, including skin substitutes, collagen matrices, and antimicrobial dressings.
- Surgical & Sports Medicine: Offers products for orthopedic and sports medicine applications, such as cartilage repair and soft tissue regeneration.
Leadership and Structure
Gary S. Gillheeney, Sr. is the President and Chief Executive Officer. The company has a standard corporate structure with a board of directors and executive leadership team overseeing various departments.
Top Products and Market Share
Key Offerings
- Apligraf: A bioengineered skin substitute used for the treatment of venous leg ulcers and diabetic foot ulcers. Apligraf holds a significant market share in the bioengineered skin substitute market, with competitors including Mimedx and Integra LifeSciences. Apligraf revenues account for a significant portion of the company's wound care segment.
- PuraPly AM: An antimicrobial barrier for wound management. Competitors include Silverlon and Acticoat. Puraply Am is another core product in the wound care segment
- NuShield: A collagen matrix wound covering. NuShield, while an important product, has many competitors in the collagen matrix market, including Integra LifeSciences and Smith & Nephew.
Market Dynamics
Industry Overview
The regenerative medicine market is experiencing strong growth driven by an aging population, increasing incidence of chronic wounds, and advancements in biotechnology.
Positioning
Organogenesis is a key player in the advanced wound care and regenerative medicine markets, with a strong portfolio of bioengineered products. Their competitive advantage lies in their established product line and clinical evidence supporting their efficacy.
Total Addressable Market (TAM)
The total addressable market for wound care is estimated to be substantial, potentially exceeding $10 billion globally. Organogenesis is well-positioned to capture a significant share of this market with its diverse product portfolio.
Upturn SWOT Analysis
Strengths
- Established product portfolio
- Strong clinical evidence
- Proprietary technology
- Experienced management team
- Established sales and marketing infrastructure
Weaknesses
- Dependence on key products
- Reimbursement risks
- Competition from larger players
- High R&D expenses
- Past regulatory scrutiny
Opportunities
- Expanding into new geographic markets
- Developing new products
- Acquiring complementary technologies
- Partnering with other companies
- Capitalizing on favorable regulatory changes
Threats
- Increasing competition
- Changing reimbursement policies
- Product liability claims
- Economic downturns
- Technological obsolescence
Competitors and Market Share
Key Competitors
- MIMD
- INTE
- BSX
- SNY
Competitive Landscape
Organogenesis faces competition from established medical device companies and smaller biotechnology firms. While Organogenesis holds a strong position in certain segments like bioengineered skin substitutes, competitors possess greater overall resources and broader product portfolios. Organogenesis must continue innovating and expanding its market reach to maintain its competitive edge.
Growth Trajectory and Initiatives
Historical Growth: Requires specific recent financial data to populate. See source documents
Future Projections: Requires specific recent financial data to populate. See source documents
Recent Initiatives: Requires specific recent details about partnerships, new initiatives. See source documents
Summary
Organogenesis is a significant player in regenerative medicine, particularly in advanced wound care. Its strong product portfolio and clinical backing are key strengths. The company faces challenges regarding competition and reimbursement, and must navigate these to achieve sustained growth. Monitoring market trends and technological advancements will be critical for Organogenesis's long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance are subject to change. Data may be based on estimates and projections.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Organogenesis Holdings Inc
Exchange NASDAQ | Headquaters Canton, MA, United States | ||
IPO Launch date 2017-01-05 | President, CEO, Chair of the Board Mr. Gary S. Gillheeney Sr. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 869 | Website https://organogenesis.com |
Full time employees 869 | Website https://organogenesis.com | ||
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, a dual-layered amniotic tissue graft used to treat chronic and acute wounds. It also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; TransCyte, a bioengineered tissue scaffold that promotes burn healing; and PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications. In addition, the company develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.